Therapeutic Targets for Malignant Peripheral nerve Sheath Tumors

References

• Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr. Oncol. Rep. 11(4), 322–328 (2009).
   PubMed Web of Science ®Google Scholar
• Carli M, Ferrari A, Mattke A et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J. Clin. Oncol. 23(33), 8422–8430 (2005).
   PubMed Web of Science ®Google Scholar
• Bates JE, Peterson CR, Dhakal S, Giampoli EJ, Constine LS. Malignant peripheral nerve sheath tumors (MPNST): a SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population. Pediatr. Blood Cancer 61(11), 1955–1960 (2014).
   PubMed Web of Science ®Google Scholar
• Farid M, Demicco EG, Garcia R et al. Malignant peripheral nerve sheath tumors. Oncologist 19(2), 193–201 (2014).
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ. Peripheral nerve sheath tumors: the elegant chapter in surgical neuropathology. Acta Neuropathol. 123(3), 293–294 (2012).
   PubMed Web of Science ®Google Scholar
• Foley KM, Woodruff JM, Ellis FT, Posner JB. Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann. Neurol. 7(4), 311–318 (1980).
   PubMed Web of Science ®Google Scholar
• Lafemina J, Qin LX, Moraco NH et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann. Surg. Oncol. 20(1), 66–72 (2013).
   PubMed Web of Science ®Google Scholar
• Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg. Clin. North Am. 19(4), 533–543; v (2008).
   PubMed Web of Science ®Google Scholar
• Stemmer-Rachamimov AO, Louis DN, Nielsen GP et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 64(10), 3718–3724 (2004).
   PubMed Web of Science ®Google Scholar
• Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma 2017, 7429697 (2017).
   PubMedGoogle Scholar
• Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am. J. Pathol. 178(5), 1932–1939 (2011).
   PubMed Web of Science ®Google Scholar
• Carroll SL. The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics. Am. J. Pathol. 186(3), 464–477 (2016).
   PubMed Web of Science ®Google Scholar
• Lothe RA, Smith-Sorensen B, Hektoen M et al. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosom. Cancer 30(2), 202–206 (2001).
   PubMed Web of Science ®Google Scholar
• Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 155(6), 1879–1884 (1999).
   PubMed Web of Science ®Google Scholar
• Beert E, Brems H, Daniels B et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosom. cancer 50(12), 1021–1032 (2011).
   PubMed Web of Science ®Google Scholar
• Bottillo I, Ahlquist T, Brekke H et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J. Pathol. 217(5), 693–701 (2009).
   PubMed Web of Science ®Google Scholar
• Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci. Rep. 7(1), 14992 (2017).
   PubMedGoogle Scholar
• Bradford D, Kim A. Current treatment options for malignant peripheral nerve sheath tumors. Curr. Treat. Options Oncol. 16(3), 328 (2015).
   PubMed Web of Science ®Google Scholar
• Kahn J, Gillespie A, Tsokos M et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front. Oncol. 4, 324 (2014).
   PubMedGoogle Scholar
• Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19(2), 117–123 (2007).
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141(7), 1117–1134 (2010).
   PubMed Web of Science ®Google Scholar
• Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol. Cancer 17(1), 34 (2018).
   PubMedGoogle Scholar
• Regad T. Targeting RTK signaling pathways in cancer. Cancers 7(3), 1758–1784 (2015).
   PubMed Web of Science ®Google Scholar
• Reilly KM. Extending the convergence of canonical WNT signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors. Cancer Discov. 3(6), 610–612 (2013).
   PubMed Web of Science ®Google Scholar
• Holtkamp N, Okuducu AF, Mucha J et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27(3), 664–671 (2006).
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J. Clin. Oncol. 27(19), 3148–3153 (2009).
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Wathen JK, Lucas DR et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 122(6), 868–874 (2016).
   PubMed Web of Science ®Google Scholar
• Du X, Yang J, Ylipaa A, Zhu Z. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. J. Hematol. Oncol. 6, 93 (2013).
   PubMed Web of Science ®Google Scholar
• Tabone-Eglinger S, Bahleda R, Cote JF et al. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008, 849156 (2008).
   PubMedGoogle Scholar
• Holtkamp N, Malzer E, Zietsch J et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro-Oncology 10(6), 946–957 (2008).
   PubMed Web of Science ®Google Scholar
• Wu J, Patmore DM, Jousma E et al. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 33(2), 173–180 (2014).
   PubMed Web of Science ®Google Scholar
• Albritton KH, Rankin C, Coffin CM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J. Clin. Oncol. 24(18_Suppl), 9518–9518 (2006).
   Web of Science ®Google Scholar
• Morrison DK. MAP kinase pathways. Cold Spring Harbor Perspect. Biol. 4(11), (2012).
   PubMed Web of Science ®Google Scholar
• Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 123(3), 321–348 (2012).
   PubMed Web of Science ®Google Scholar
• Maki RG, D'adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133–3140 (2009).
   PubMed Web of Science ®Google Scholar
• Jessen WJ, Miller SJ, Jousma E et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123(1), 340–347 (2013).
   PubMed Web of Science ®Google Scholar
• Dombi E, Baldwin A, Marcus LJ et al. Activity of selumetinib in neurofibromatosis Type 1-related plexiform neurofibromas. New Engl. J. Med. 375(26), 2550–2560 (2016).
   PubMed Web of Science ®Google Scholar
• Endo M, Yamamoto H, Setsu N et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin. Cancer Res. 19(2), 450–461 (2013).
   PubMed Web of Science ®Google Scholar
• Johansson G, Mahller YY, Collins MH et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol. Cancer Ther. 7(5), 1237–1245 (2008).
   PubMed Web of Science ®Google Scholar
• De Raedt T, Walton Z, Yecies JL et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3), 400–413 (2011).
   PubMed Web of Science ®Google Scholar
• Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harbor Perspect. Med. 2(7), a006502 (2012).
   PubMed Web of Science ®Google Scholar
• D'adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Widemann BC, Meyer CF, Cote GM et al. SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J. Clin. Oncol. 34(15_suppl), 11053–11053 (2016).
   Web of Science ®Google Scholar
• Rahrmann EP, Watson AL, Keng VW et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat. Genet. 45(7), 756–766 (2013).
   PubMed Web of Science ®Google Scholar
• Hu T, Li C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol. Cancer 9, 236 (2010).
   PubMed Web of Science ®Google Scholar
• Mo W, Chen J, Patel A et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 152(5), 1077–1090 (2013).
   PubMed Web of Science ®Google Scholar
• Watson AL, Rahrmann EP, Moriarity BS et al. Canonical Wnt/beta-catenin signaling drives human Schwann cell transformation, progression, and tumor maintenance. Cancer Discov 3(6), 674–689 (2013).
   PubMed Web of Science ®Google Scholar
• Lee W, Teckie S, Wiesner T et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46(11), 1227–1232 (2014).
   PubMed Web of Science ®Google Scholar
• De Raedt T, Beert E, Pasmant E et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514(7521), 247–251 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang Y, Jones S et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Gen. 46(11), 1170–1172 (2014).
   PubMed Web of Science ®Google Scholar
• Pasini D, Malatesta M, Jung HR et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 38(15), 4958–4969 (2010).
   PubMed Web of Science ®Google Scholar
• Patel AJ, Liao CP, Chen Z, Liu C, Wang Y, Le LQ. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep. 6(1), 81–92 (2014).
   PubMed Web of Science ®Google Scholar
• Lopez G, Torres K, Liu J et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 71(1), 185–196 (2011).
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat. Rev. Cancer 13(4), 246–257 (2013).
   PubMed Web of Science ®Google Scholar
• Jacoby LB, Maccollin M, Barone R, Ramesh V, Gusella JF. Frequency and distribution of NF2 mutations in schwannomas. Genes, Chromosom. Cancer 17(1), 45–55 (1996).
   PubMed Web of Science ®Google Scholar
• Gehlhausen JR, Park SJ, Hickox AE et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human Schwannoma formation. Hum. Mol. Genet. 24(1), 1–8 (2015).
   PubMed Web of Science ®Google Scholar
• Murakami H, Mizuno T, Taniguchi T et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71(3), 873–883 (2011).
   PubMed Web of Science ®Google Scholar
• Fullenkamp CA, Hall SL, Jaber OI et al. TAZ and YAP are frequently activated oncoproteins in sarcomas. Oncotarget 7(21), 30094–30108 (2016).
   PubMedGoogle Scholar
• Zanconato F, Battilana G, Cordenonsi M, Piccolo S. YAP/TAZ as therapeutic targets in cancer. Curr. Opin. Pharmacol. 29, 26–33 (2016).
   PubMed Web of Science ®Google Scholar
• Wu LM, Deng Y, Wang J et al. Programming of Schwann Cells by Lats1/2-TAZ/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell 33 (2018).
   Web of Science ®Google Scholar
• Liu-Chittenden Y, Huang B, Shim JS et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26(12), 1300–1305 (2012).
   PubMed Web of Science ®Google Scholar
• Song S, Honjo S, Jin J et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin. Cancer Res. 21(11), 2580–2590 (2015).
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhang Z, Rodriguez-Barrueco R et al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget 7(20), 28976–28988 (2016).
   PubMedGoogle Scholar
• Huggett MT, Jermyn M, Gillams A et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br. J. Cancer 110(7), 1698–1704 (2014).
   PubMed Web of Science ®Google Scholar
• Jiao S, Wang H, Shi Z et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25(2), 166–180 (2014).
   PubMed Web of Science ®Google Scholar
• Song S, Xie M, Scott AW et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol. Cancer Ther. 17(2), 443–454 (2018).
   PubMed Web of Science ®Google Scholar
• Bhavsar C, Momin M, Khan T, Omri A. Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies. Exp. Opin. Drug Deliv. 15(7), 641–663 (2018).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296(5569), 920–922 (2002).
   PubMed Web of Science ®Google Scholar
• Wu J, Williams JP, Rizvi TA et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 13(2), 105–116 (2008).
   PubMed Web of Science ®Google Scholar
• Prada CE, Jousma E, Rizvi TA et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 125(1), 159–168 (2013).
   PubMed Web of Science ®Google Scholar
• Patwardhan PP, Surriga O, Beckman MJ et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin. Cancer Res. 20(12), 3146–3158 (2014).
   PubMed Web of Science ®Google Scholar
• Shurell E, Singh AS, Crompton JG et al. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget 7(39), 64300–64308 (2016).
   PubMedGoogle Scholar
• Budczies J, Mechtersheimer G, Denkert C et al. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology 6(3), e1279777 (2017).
   PubMed Web of Science ®Google Scholar
• Antoszczyk S, Spyra M, Mautner VF et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro-Oncology 16(8), 1057–1066 (2014).
   PubMed Web of Science ®Google Scholar
• Mahller YY, Vaikunth SS, Currier MA et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther. 15(2), 279–286 (2007).
   PubMed Web of Science ®Google Scholar